Your new experience awaits. Try the new design now and help us make it even better

ORIGINAL RESEARCH article

Front. Immunol.

Sec. Cancer Immunity and Immunotherapy

Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1634399

This article is part of the Research TopicEpigenetic Alterations that Facilitate Aggressive Disease or Metastasis in Breast CancersView all 4 articles

Integrative Bioinformatics and Experimental Validation Unveil CRISP3 as a Hypoxia-, Epithelial Mesenchymal Transition-, and Immune-Related Prognostic Biomarker and Therapeutic Target in Breast Cancer

Provisionally accepted
Yuanyuan  RenYuanyuan Ren1Yirong  LiYirong Li1Yue  CuiYue Cui1Yaning  ZhangYaning Zhang1Nan  CaoNan Cao1Yi  YuYi Yu1*Yahuan  GuoYahuan Guo2Xu  LiXu Li2
  • 1Northwest University, Xi'an, China
  • 2Shaanxi Provincial Cancer Hospital, Xi'an, Shaanxi, China

The final, formatted version of the article will be published soon.

Introduction Breast cancer (BC) remains a widespread malignancy and ranks as the second leading cause of cancer-related mortality among women worldwide. Hypoxia, epithelial-mesenchymal transition (EMT), and immune-related processes have been increasingly recognized as critical contributors to BC pathogenesis. However, a prognostic model integrating hypoxia-, EMT-, and immune-related genes (HEMTIRGs) to predict BC outcomes has not yet been established. Methods Gene expression datasets of BC patients were obtained from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO). Prognostic genes were identified using Least Absolute Shrinkage and Selection Operator (LASSO) Cox regression analysis. A prognostic model was developed based on these genes. Immune infiltration was assessed using CIBERSORT and ssGSEA analyses. Immunotherapy response was predicted using the tumor immune dysfunction and exclusion (TIDE) algorithm. Functional roles of HEMTIRGs in BC malignancy were validated through in vitro experiments. Results In this study, four HEMTIRGs (PAX7, DCD, CRISP3, and FGG) were identified and used to develop a prognostic model. Patients were stratified into high- and low-risk groups based on median risk scores. A nomogram based on this model accurately predicted overall survival (OS), consistent with the observed outcomes. Notably, patients in the high-risk group exhibited increased immune cell infiltration but a lower predicted response to immunotherapy. Immunohistochemistry (IHC) further confirmed that HEMTIRGs expression levels were strongly associated with breast cancer, with CRISP3 showing the most pronounced upregulation. In vitro functional assays demonstrated that CRISP3 promoted malignant phenotypes of breast cancer cells under hypoxic conditions through activation of the IL-17/AKT signaling pathway. Conclusion This study establishes a novel HEMTIRGs-based prognostic model for BC, offering a robust tool for predicting patient prognosis and immunotherapy efficacy. Additionally, our findings provide new insights into BC pathogenesis, highlighting potential therapeutic targets.

Keywords: breast cancer, hypoxia, Epithelial-Mesenchymal Transition, prognosis, Model, Immunotherapy

Received: 24 May 2025; Accepted: 30 Sep 2025.

Copyright: © 2025 Ren, Li, Cui, Zhang, Cao, Yu, Guo and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Yi Yu, yiyu@nwu.edu.cn

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.